Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14754859 | 0.82 | PDE4A (0.47) | PDE4APDE4BPDE4DPDE4CMYC | |
| SCHEMBL21211239 | 0.81 | PDE4A (0.49) | PDE4APDE4BPDE4DPDE4CMYC | |
| SCHEMBL25054415 | 0.77 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4CMYC | |
| SCHEMBL25054383 | 0.77 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4CMYC | |
| SCHEMBL15308512 | 0.77 | PDE4A (0.41) | PDE4APDE4BPDE4DPDE4CDYRK1A | |
| SCHEMBL17121438 | 0.73 | PDE4A (0.48) | PDE4APDE4BPDE4DPDE4CDYRK1A | |
| SCHEMBL15306525 | 0.72 | PDE4A (0.35) | PDE4APDE4BPDE4DPDE4CDYRK1A | |
| SCHEMBL21863419 | 0.69 | PDE4A (0.41) | PDE4APDE4BPDE4DPDE4CDYRK1A | |
| SCHEMBL13080314 | 0.69 | PDE4A (0.48) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL13080991 | 0.69 | PDE4A (0.41) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PDE4A 368/4885PDE4B 338/4885PDE4D 449/4885 |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PDE4A 368/4885PDE4B 338/4885PDE4D 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.